Survival of a 118-patient subpopulation8-150 with CMML according to risk groups based on the MDAPS
| Risk group . | No. of patients (%) . | No. of deaths . | Percentiles of survival (mo) . | P (log-rank test) . | ||
|---|---|---|---|---|---|---|
| 75% . | 50% . | 25% . | ||||
| Low | 30 (25) | 17 | 16 | 26 | 58 | < .01 |
| Intermediate-1 | 42 (36) | 31 | 4 | 14 | 29 | |
| Intermediate-2 | 35 (30) | 29 | 3 | 9 | 18 | |
| High | 11 (9) | 9 | 3 | 5 | 8 | |
| Risk group . | No. of patients (%) . | No. of deaths . | Percentiles of survival (mo) . | P (log-rank test) . | ||
|---|---|---|---|---|---|---|
| 75% . | 50% . | 25% . | ||||
| Low | 30 (25) | 17 | 16 | 26 | 58 | < .01 |
| Intermediate-1 | 42 (36) | 31 | 4 | 14 | 29 | |
| Intermediate-2 | 35 (30) | 29 | 3 | 9 | 18 | |
| High | 11 (9) | 9 | 3 | 5 | 8 | |
Analysis based on patients who met the following criteria: IMCs below 10%, monocytes above 10%, and basophils above 2%.